Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2026)
Immunocore Holdings (IMCR) posted Total Non-Current Liabilities of $609.3 million for Q3 2025, little changed sequentially from $609.9 million in Q2 2025, and down 13.42% YoY from $703.8 million in Q3 2024.
Analysis
Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Immunocore Holdings has reported Total Non-Current Liabilities for 7 years, with the latest figure at $609.3 million in Q3 2025.
- Quarterly Total Non-Current Liabilities fell 13.42% year-over-year to $609.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $609.3 million (down 13.42% YoY) and the FY2024 annual result came in at $648.8 million, up 185.58% from the prior year.
- Total Non-Current Liabilities held at $609.3 million in Q3 2025 per IMCR's latest filing, from $609.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $703.8 million in Q3 2024 and troughed at $85.6 million in Q3 2022.
- A 5-year average of $419.5 million and a median of $598.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities decreased 18.84% in 2021, then surged 647.38% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $93.1 million in 2021, then declined by 7.16% to $86.4 million in 2022, then soared by 162.9% to $227.2 million in 2023, then surged by 185.58% to $648.8 million in 2024, then dropped by 6.08% to $609.3 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $609.3 million, $609.9 million, and $587.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Immunocore Holdings | 1.85 Bn | 965.54 Mn | 114.84 Mn | 672.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 672.74 Mn |
| Dec 31, 2025 | 686.24 Mn |
| Sep 30, 2025 | 609.33 Mn |
| Jun 30, 2025 | 609.95 Mn |
| Mar 31, 2025 | 587.05 Mn |
| Dec 31, 2024 | 648.79 Mn |
| Sep 30, 2024 | 703.81 Mn |
| Jun 30, 2024 | 662.14 Mn |
| Mar 31, 2024 | 632.29 Mn |
| Dec 31, 2023 | 227.18 Mn |
| Jun 30, 2023 | 88.60 Mn |
| Dec 31, 2022 | 86.41 Mn |
| Sep 30, 2022 | 85.61 Mn |
| Dec 31, 2021 | 93.07 Mn |
| Dec 31, 2020 | 114.68 Mn |
| Dec 31, 2019 | 111.04 Mn |